Grail
Menlo Park
About Grail
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $2.4B
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:GRAL
- Website: grail.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/grail-15794 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.